International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Richard

Warren

,

BSc, MBChB, MRCP, PhD

Professor of Dermatology and Therapeutics and Honorary Consultant Dermatologist
University of Manchester
Salford
,
United Kingdom
Professor Richard Warren is a Professor of Dermatology and Therapeutics and Honorary Consultant Dermatologist. He graduated from Liverpool University with a first-class honors degree in Pharmacology and gained his Medical degree, with honors, one year later. He was awarded The J Hill Abram prize — the highest mark in Medicine and the Reginald Dora Goodrick prize — highest mark in Surgery. His work in dermatology has focused on: pharmacogenetics (forming the basis of his PhD thesis), the genetic susceptibility to psoriasis, and more recently, biological therapies and their use in the treatment of psoriasis. For his work into the pharmacogenetics of methotrexate, he has received national and international awards from the British Association of Dermatologists (BAD) and the American Academy of Dermatology. He is widely published in the field of Dermatology with numerous abstracts, papers, and book contributions including The Lancet, Nature Genetics, and The Journal of Investigative Dermatology. He is currently the EU Editor-in-Chief for the journal Dermatology and Therapy. He has been an invited plenary speaker at major national and international dermatology meetings and is Councilor with The International Psoriasis Council. He currently chairs the BAD guideline group for methotrexate and is a member of the BAD biologics committee and research subcommittee. In 2012, he was the expert panel member on the National Institute for Health and Clinical Excellence guideline group for psoriasis. He is co-leader of one of the two workstreams involved in the successful funding from the Medical Research Council stratified medicine grant (Value £7 million) — Psoriasis Stratification to Optimise Relevant Therapies (PSORT). He is the Chief Investigator on the largest psoriasis study currently running in the UK, known as SIGNATURE, investigating a new biological therapy for the treatment of severe psoriasis. He is the principal investigator at Salford Royal NHS Foundation Trust for BADBIR, a large-scale pharmacovigilance study, and he led the team to the award for the highest recruiting center in 2012. He co-established a clinic for patients with severe psoriasis and psoriatic arthritis in 2010 with Dr. Hector Chinoy, and the clinic has received wide acclaim and is used as a national exemplar.
Last Updated:
01/25/2022

Languages Spoken

English